Abu Dhabi’s Mubadala has partnered with US-based private equity firm Kohlberg to acquire a majority share in PCI Pharma Services, a U.S. pharmaceutical outsourcing company, from Partners Group.
Following the sale, to private equity firm Kohlberg and Mubadala, Partners Group will retain a meaningful minority equity stake in the Company. The terms of the transaction are not disclosed.
PCI Pharma Services
Headquartered in Philadelphia, Pennsylvania, PCI Pharma Services is a recognized industry leader and trusted partner providing a broad range of integrated pharmaceutical supply chain solutions from the earliest stages of drug development through to commercial launch and delivering ongoing supply with global capabilities for drug development & manufacturing, clinical trials services and commercial packaging services. PCI spans a global footprint of 25 GMP facilities across six countries and employs ~3900 people worldwide.
Kohlberg and Mubadala plan to partner with PCl’s management team, led by CEO Salim Haffar, to continue the Company’s transformation journey by adding specific capabilities and geographies organically and inorganically to improve its customer service experience and enable its customers to bring lifesaving biopharmaceutical therapies to market. Leveraging the global growth trends in biologics and specialized drug therapies, future capabilities include sterile fill-finish of injectables, expanding high potent and specialized manufacturing and further geographic expansion into Asia and greater Europe.
Mubadala has been looking to increase its investment in the healthcare sector, focusing on life sciences and medical technology.
Mubadala Investment Company
Mubadala, which manages about $230 billion in assets, is the second-biggest state investor in the UAE, after Abu Dhabi Investment Authority which is estimated to have nearly $700 billion in assets.
